Theravance Biopharma Inc TBPH.OQ TBPH.O is expected to show a rise in quarterly revenue when it reports results on February 24 (estimated) for the period ending December 31 2025
The George Town Grand Cayman-based company is expected to report a 171.2% increase in revenue to $50.86 million from $18.75 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Theravance Biopharma Inc is for earnings of $1.13 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Theravance Biopharma Inc is $27.00, about 39% above its last closing price of $19.43
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.14 | -0.13 | 0.07 | Beat | 154.5 |
Jun. 30 2025 | 0.80 | 0.67 | -0.54 | Missed | -180.2 |
Mar. 31 2025 | -0.23 | -0.23 | -0.27 | Missed | -18.4 |
Dec. 31 2024 | -0.25 | -0.21 | -0.31 | Missed | -47.6 |
Sep. 30 2024 | -0.24 | -0.23 | -0.26 | Missed | -12.6 |
Jun. 30 2024 | -0.22 | -0.21 | -0.28 | Missed | -35.6 |
Mar. 31 2024 | -0.22 | -0.25 | -0.24 | Beat | 5.5 |
Dec. 31 2023 | -0.17 | -0.15 | -0.17 | Missed | -14.3 |
This summary was machine generated February 20 at 21:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)